The difference between imported and domestically produced Pembrolizumab

Pembrolizumab currently on the market in China is an imported drug, and there are no domestic drugs produced by domestic pharmaceutical companies on the market. Pembrolizumab is an immune checkpoint inhibitor used to treat many types of cancer. It enhances the ability of immune cells to attack tumor cells by inhibiting the PD-1 receptor in the immune system.

Studies have shown that pembrolizumab has shown good efficacy in the treatment of malignant melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma and head and neck squamous cell carcinoma. Pembrolizumab may be a first-line treatment option for patients with advanced or metastatic malignant melanoma. Clinical trial results show that approximately 40-45% of patients with malignant melanoma treated with pembrolizumab experienced partial or complete response. Pembrolizumab is also used to treat other types of cancer, such as renal cell carcinoma, Hodgkin lymphoma and squamous cell carcinoma of the head and neck. For patients with these cancers, pembrolizumab may provide an effective treatment option.

Pembrolizumab original drug, specifications100mg/4ml, may be priced around RMB 15,000 per box on the domestic market. This drug is a strictly controlled drug and has not yet been included in medical insurance. Pembrolizumab The price of the European version of the original drug 100mg/4ml per box may be around RMB 25,000, and the price of the Turkish version of 100mg/4ml per box may be around 10,000 RMB (the price may fluctuate due to the exchange rate). The ingredients of the original drugs at home and abroad are basically the same, and they are expensive. There are currently no generic versions of Pembrolizumab available overseas.